サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1737526

製薬におけるAIの世界市場

Artificial Intelligence in Pharmaceutical

出版日
ページ情報
英文 245 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.12円
製薬におけるAIの世界市場
出版日: 2025年05月30日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 245 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

製薬におけるAIの世界市場は2030年までに58億米ドルに達する見込み

2024年に12億米ドルと推定される製薬におけるAIの世界市場は、分析期間2024-2030年にCAGR 30.1%で成長し、2030年には58億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるAIハードウェアは、CAGR 31.6%を記録し、分析期間終了時には36億米ドルに達すると予測されます。AIソフトウェア分野の成長率は、分析期間でCAGR 27.0%と推定されます。

米国市場は3億1,450万米ドルと推定、中国はCAGR 28.5％で成長予測

米国の製薬におけるAI市場は、2024年に3億1,450万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを28.5%として、2030年までに8億7,370万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ27.7%と25.9%と予測されています。欧州では、ドイツがCAGR 20.8%で成長すると予測されています。

世界の製薬におけるAI市場- 主要動向と促進要因まとめ

なぜAIが医薬品業界のゲームチェンジャーになりつつあるのか？

AI（人工知能）は、医薬品の発見、開発、製造、市場投入の方法を再構築することで、製薬業界を急速に変革しつつあります。医薬品開発のコスト、時間、データ量が増大する中、AIは研究開発のワークフローを合理化し、新薬候補を特定し、臨床試験デザインを最適化する強力なツールを提供しています。従来の製薬モデルは、1つの医薬品を上市するのに10年以上と数十億米ドルを要することが多く、高い開発中止率を伴う。AI、特に機械学習（ML）とディープラーニングは、ヒット・トゥ・リードの同定、化合物の有効性と毒性の予測、既存薬の再利用をより正確かつ迅速に行うことで、こうした非効率性に対処しています。

オミックスデータや電子カルテから生物医学文献や分子ライブラリーまで、膨大なデータセットを分析するAIの能力は、より的を絞った仮説駆動型の創薬アプローチを可能にします。製薬会社はAIを活用して疾患メカニズムと治療経路の隠れた関係を明らかにし、初期段階の研究開発における試行錯誤の要素を大幅に減らしています。さらにAIは、医師への働きかけのパーソナライズ、価格戦略の最適化、需要予測、患者のアドヒアランス向上など、商業活動にも導入されています。製薬企業がデータ中心のイノベーションモデルへと移行する中、AIは競争優位性と業務の俊敏性の中心的存在になりつつあります。

AI主導のプラットフォームはどのように創薬と臨床開発を加速しているか？

AIは、予測モデリング、分子シミュレーション、自動化されたハイスループットスクリーニングを通じて、創薬のタイムラインを大幅に短縮しています。膨大な化合物データセットで訓練されたディープラーニング・アルゴリズムは、生物学的活性、結合親和性、ADMET（吸収、分布、代謝、排泄、毒性）特性、オフターゲット効果を予測することができ、研究者は最も有望な候補化合物に集中することができます。また、自然言語処理（NLP）ツールは、科学文献や臨床試験データベースから実用的な知見を抽出し、標的の検証や仮説生成を充実させています。

臨床開発では、AIが臨床試験のデザインと実施を変革しています。機械学習モデルは、最適な治験実施施設の特定、患者募集率の予測、遺伝的または表現型データに基づく治療に最も反応する可能性の高い集団の選択に使用されています。AIを活用した遠隔モニタリングと実データ統合は、適応的な試験デザインと市販後サーベイランスを強化し、安全性評価と規制遵守の両方を向上させています。このような効率化により、コストと減少が削減されるだけでなく、個別化医療のパラダイムに沿った精密試験への道が開かれます。AIが創薬と送達のギャップを埋め続けることで、医薬品開発ライフサイクルは、より迅速で、より予測可能な、患者中心のプロセスへと再構築されつつあります。

製薬におけるAIの導入はどこで加速し、どの利害関係者が先導しているのか？

製薬におけるAIの導入は北米、欧州、アジア太平洋で加速しており、投資、パートナーシップ、AIスタートアップの活動では米国がリードしています。ファイザー、ノバルティス、ロシュ、アストラゼネカ、サノフィなどの世界製薬大手は、AIファーストのバイオテクノロジー企業や学術機関と積極的に提携し、独自のアルゴリズムや次世代創薬エンジンを共同開発しています。グーグル（ディープマインド）、IBMワトソンヘルス、エヌビディアなどの大手ハイテク企業も製薬会社と提携し、生物医学研究に合わせたコンピューティング・インフラやAIプラットフォームを提供しています。

欧州はAIを活用した医薬品イノベーションの拠点として台頭しており、特に英国、ドイツ、スイスでは強力なバイオテクノロジー・エコシステムと政府資金がセクターを超えたコラボレーションを促進しています。中国と韓国が主導するアジア太平洋は、国家AI戦略、人口規模の健康データセット、急速に進歩する臨床試験能力によって力強い成長を遂げています。BenevolentAI、Insilico Medicine、Recursion、Atomwiseなど、創薬AIを専門とする新興企業は、ケムインフォマティクス、バイオインフォマティクス、予測分析を統合したスケーラブルなプラットフォームを提供することで人気を集めています。CRO（医薬品開発業務受託機関）やCDMO（医薬品開発業務受託機関）もAIを統合して、臨床段階や商業段階でのサービス提供を強化しています。

製薬分野におけるAIの世界の成長の原動力は？

製薬におけるAI市場の成長は、医薬品開発のコストと複雑性の増大、生物医学データの爆発的増加、精密医療へのシフトなど、いくつかの集約的な要因によって牽引されています。主な促進要因は、ゲノム、プロテオミクス、画像、EHR、市場インテリジェンスにまたがる多次元データセットを統合・分析し、エビデンスに基づく迅速な意思決定をサポートするAIシステムの能力が高まっていることです。規制当局もAIを活用したイノベーションに寛容な姿勢を示しており、FDAとEMAは実データ利用、アルゴリズムの透明性、デジタルバイオマーカーの検証に関するガイダンスを提供しています。

ベンチャーキャピタルからの投資、M&A活動、製薬会社とAIベンダー間の戦略的提携は、イノベーション・パイプラインを加速させています。COVID-19パンデミックは、治療モデリング、ワクチン開発、疫学的追跡におけるAIの役割をさらに実証し、AIの拡張性と影響力に対する組織の信頼を強化しました。クラウド・コンピューティング、データ相互運用性の向上、連携学習モデルも、世界なデータ・サイロをまたいだ安全で大規模なモデル学習を可能にすることで、AI導入の障壁を減らしています。AIがエンド・ツー・エンドの製薬業務に組み込まれるにつれ、重要な戦略的疑問が浮かび上がってきます。製薬業界はAIを十分に活用することで、開発期間を短縮し、失敗率を減らし、より安全で効果的な治療法をこれまで以上に迅速に患者に提供できるのだろうか？

セグメント

提供（ハードウェア、ソフトウェア、サービス）、テクノロジー（自然言語処理、コンテキスト認識処理、ディープラーニング、クエリー手法、その他テクノロジー）、薬剤タイプ（大型分子、小型分子）、アプリケーション（創薬、臨床試験、研究開発、医薬品製造・サプライチェーン、その他アプリケーション）、エンドユーザー（製薬・バイオテクノロジー企業、病院・診断センター、学術・研究機関、その他エンドユーザー）

調査対象企業の例（注目の41社）

  • Absci Corporation
  • Anima Biotech
  • Antiverse
  • Atomwise
  • BenevolentAI
  • BPGbio
  • Cloud Pharmaceuticals
  • Deep Genomics
  • Exscientia
  • Generate Biomedicines
  • GNS Healthcare
  • Healx
  • IBM Watson Health
  • Iktos
  • Insilico Medicine
  • Insitro
  • InveniAI
  • Isomorphic Labs
  • Microsoft Corporation
  • Model Medicines

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP33464

Global Artificial Intelligence in Pharmaceutical Market to Reach US$5.8 Billion by 2030

The global market for Artificial Intelligence in Pharmaceutical estimated at US$1.2 Billion in the year 2024, is expected to reach US$5.8 Billion by 2030, growing at a CAGR of 30.1% over the analysis period 2024-2030. AI Hardware, one of the segments analyzed in the report, is expected to record a 31.6% CAGR and reach US$3.6 Billion by the end of the analysis period. Growth in the AI Software segment is estimated at 27.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$314.5 Million While China is Forecast to Grow at 28.5% CAGR

The Artificial Intelligence in Pharmaceutical market in the U.S. is estimated at US$314.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$873.7 Million by the year 2030 trailing a CAGR of 28.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 27.7% and 25.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 20.8% CAGR.

Global Artificial Intelligence in Pharmaceutical Market - Key Trends & Drivers Summarized

Why Is Artificial Intelligence Becoming a Game-Changer in the Pharmaceutical Industry?

Artificial Intelligence (AI) is rapidly transforming the pharmaceutical industry by reshaping how drugs are discovered, developed, manufactured, and brought to market. As drug development becomes increasingly costly, time-intensive, and data-heavy, AI offers powerful tools to streamline R&D workflows, identify novel drug candidates, and optimize clinical trial design. Traditional pharma models often take over a decade and billions of dollars to bring a single drug to market, with high attrition rates. AI, particularly machine learning (ML) and deep learning, is addressing these inefficiencies by accelerating hit-to-lead identification, predicting compound efficacy and toxicity, and repurposing existing drugs with greater precision and speed.

AI's ability to analyze vast datasets-ranging from omics data and electronic health records to biomedical literature and molecular libraries-enables a more targeted and hypothesis-driven approach to drug discovery. Pharma companies are leveraging AI to uncover hidden relationships between disease mechanisms and therapeutic pathways, drastically reducing the trial-and-error component of early-stage R&D. Additionally, AI is being deployed in commercial operations to personalize physician outreach, optimize pricing strategies, forecast demand, and improve patient adherence. As pharma transitions toward data-centric innovation models, AI is becoming central to competitive advantage and operational agility.

How Are AI-Driven Platforms Accelerating Drug Discovery and Clinical Development?

AI is significantly compressing timelines in drug discovery through predictive modeling, molecular simulations, and automated high-throughput screening. Deep learning algorithms trained on vast compound datasets can predict biological activity, binding affinity, ADMET (absorption, distribution, metabolism, excretion, and toxicity) properties, and off-target effects, allowing researchers to focus on the most promising candidates. Generative AI models are designing entirely new molecular structures with desired properties, while natural language processing (NLP) tools extract actionable insights from scientific literature and clinical trial databases, enriching target validation and hypothesis generation.

In clinical development, AI is transforming trial design and execution. Machine learning models are being used to identify optimal trial sites, predict patient recruitment rates, and select populations most likely to respond to therapy based on genetic or phenotypic data. AI-enabled remote monitoring and real-world data integration are enhancing adaptive trial designs and post-market surveillance, improving both safety assessments and regulatory compliance. These efficiencies not only reduce cost and attrition but also open the door to precision trials that align with personalized medicine paradigms. As AI continues to bridge the gap between discovery and delivery, it is reshaping the pharmaceutical development lifecycle into a faster, more predictive, and patient-centric process.

Where Is Adoption of AI in Pharmaceuticals Accelerating and Which Stakeholders Are Leading the Charge?

AI adoption in the pharmaceutical industry is accelerating across North America, Europe, and Asia-Pacific, with the U.S. leading in terms of investment, partnerships, and AI start-up activity. Global pharma leaders such as Pfizer, Novartis, Roche, AstraZeneca, and Sanofi are actively partnering with AI-first biotech firms and academic institutions to co-develop proprietary algorithms and next-gen drug discovery engines. Major tech players like Google (DeepMind), IBM Watson Health, and NVIDIA are also collaborating with pharma to provide computing infrastructure and AI platforms tailored for biomedical research.

Europe is emerging as a hub for AI-powered pharmaceutical innovation, particularly in the U.K., Germany, and Switzerland, where strong biotech ecosystems and government funding are fueling cross-sector collaboration. Asia-Pacific, led by China and South Korea, is seeing robust growth driven by national AI strategies, population-scale health datasets, and rapidly advancing clinical trial capabilities. Startups specializing in AI for drug discovery, such as BenevolentAI, Insilico Medicine, Recursion, and Atomwise, are gaining traction by offering scalable platforms that integrate cheminformatics, bioinformatics, and predictive analytics. CROs (Contract Research Organizations) and CDMOs (Contract Development and Manufacturing Organizations) are also integrating AI to enhance service offerings across clinical and commercial stages.

What Is Driving the Global Growth of AI in the Pharmaceutical Sector?

The growth in the artificial intelligence in pharmaceutical market is driven by several converging factors, including the escalating cost and complexity of drug development, the explosion of biomedical data, and the shift toward precision medicine. A primary driver is the increasing ability of AI systems to integrate and analyze multidimensional datasets-spanning genomics, proteomics, imaging, EHRs, and market intelligence-to support faster, evidence-based decisions. Regulatory agencies are also showing openness to AI-enabled innovations, with the FDA and EMA providing guidance on real-world data use, algorithm transparency, and digital biomarker validation.

Venture capital investment, M&A activity, and strategic alliances between pharma and AI vendors are accelerating innovation pipelines. The COVID-19 pandemic further validated AI’s role in therapeutic modeling, vaccine development, and epidemiological tracking, reinforcing institutional confidence in AI's scalability and impact. Cloud computing, improved data interoperability, and federated learning models are also reducing the barriers to AI adoption by enabling secure, large-scale model training across global data silos. As AI becomes embedded in end-to-end pharmaceutical operations, a critical strategic question emerges: Can the pharmaceutical industry fully harness AI to shorten development timelines, reduce failure rates, and bring safer, more effective therapies to patients faster than ever before?

SCOPE OF STUDY:

The report analyzes the Artificial Intelligence in Pharmaceutical market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Offering (Hardware, Software, Services); Technology (Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method, Other Technologies); Drug Type (Large Molecules, Small Molecules); Application (Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain, Other Applications); End-User (Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • Absci Corporation
  • Anima Biotech
  • Antiverse
  • Atomwise
  • BenevolentAI
  • BPGbio
  • Cloud Pharmaceuticals
  • Deep Genomics
  • Exscientia
  • Generate Biomedicines
  • GNS Healthcare
  • Healx
  • IBM Watson Health
  • Iktos
  • Insilico Medicine
  • Insitro
  • InveniAI
  • Isomorphic Labs
  • Microsoft Corporation
  • Model Medicines

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Artificial Intelligence in Pharmaceutical - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • AI-Driven Drug Discovery Reduces Preclinical Development Timelines Across Therapeutic Areas
    • Machine Learning Enhances Candidate Molecule Screening and Predictive Toxicology in Pharma
    • Clinical Trial Design Optimization Through AI Improves Patient Stratification and Endpoint Selection
    • Integration of AI in Drug Repurposing Unlocks New Revenue Paths for Established Pharma Pipelines
    • Virtual Screening and De Novo Drug Design Tools Accelerate Innovation in Pharma R&D
    • AI-Enhanced Pharmacovigilance Improves Real-Time Detection of Adverse Drug Reactions
    • Regulatory Engagement With AI-Supported Submissions Encourages Broader Pharmaceutical Adoption
    • Natural Language Processing Automates Literature Review and IP Landscape Analysis for Drug Development
    • AI Integration in Manufacturing Quality Control Improves Yield and Reduces Batch Failures
    • Oncology and Rare Disease Drug Pipelines See Early Wins Through AI-Augmented Discovery
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Artificial Intelligence in Pharmaceutical Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Hardware by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Hardware by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Software by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Software by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Small Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Small Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Large Molecules by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Large Molecules by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Discovery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Drug Discovery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Clinical Trial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Clinical Trial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Research & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Drug Manufacturing & Supply Chain by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Drug Manufacturing & Supply Chain by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Hospitals & Diagnostic Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Hospitals & Diagnostic Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Academic & Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Academic & Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Natural Language Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World 6-Year Perspective for Natural Language Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Context-aware Processing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 35: World 6-Year Perspective for Context-aware Processing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 36: World Recent Past, Current & Future Analysis for Deep Learning by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 37: World 6-Year Perspective for Deep Learning by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Querying Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World 6-Year Perspective for Querying Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 41: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 42: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 46: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 48: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 52: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 54: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 58: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 60: Canada Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Canada 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 64: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 66: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 70: Japan Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Japan 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 72: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 76: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 78: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 82: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 83: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 84: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 88: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 90: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 94: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 96: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 100: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 102: France Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: France 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 106: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 108: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 112: Germany Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Germany 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 114: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 118: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 120: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 124: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 126: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 130: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 132: UK Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: UK 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 136: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 138: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 142: Rest of Europe Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Rest of Europe 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Artificial Intelligence in Pharmaceutical Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 144: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 148: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 149: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 150: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 151: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 154: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Offering - Hardware, Software and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 155: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Offering - Percentage Breakdown of Value Sales for Hardware, Software and Services for the Years 2025 & 2030
    • TABLE 156: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Drug Type - Small Molecules and Large Molecules - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 157: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Drug Type - Percentage Breakdown of Value Sales for Small Molecules and Large Molecules for the Years 2025 & 2030
    • TABLE 158: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Application - Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Application - Percentage Breakdown of Value Sales for Drug Discovery, Clinical Trial, Research & Development, Drug Manufacturing & Supply Chain and Other Applications for the Years 2025 & 2030
    • TABLE 160: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by End-user - Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by End-user - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Hospitals & Diagnostic Centers, Academic & Research Institutes and Other End-Users for the Years 2025 & 2030
    • TABLE 162: Rest of World Recent Past, Current & Future Analysis for Artificial Intelligence in Pharmaceutical by Technology - Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 163: Rest of World 6-Year Perspective for Artificial Intelligence in Pharmaceutical by Technology - Percentage Breakdown of Value Sales for Natural Language Processing, Context-aware Processing, Deep Learning, Querying Method and Other Technologies for the Years 2025 & 2030

IV. COMPETITION